34504
document
The effects of candesartan on diabetes glomerulopathy : a double-blind , placebo-controlled trial . Our objective was to study the effects of candesartan on diabetic glomerulopathy in young normoalbuminuric and normotensive patients with type 1 diabetes in a double-blind , placebo-controlled trial . In 13 patients aged 24 years at baseline , we evaluated blood pressure , kidney biopsies and kidney function tests at baseline and after 5 years of treatment . Kidney biopsies were examined with light and electron microscopy , glomerular filtration rate and effective renal plasma flow determined with inulin and para-aminohippuric acid clearances . Two patients in the placebo group needed antihypertensive treatment because they developed microalbuminuria and/or hypertension , but no patient in the candesartan group did . A significant reduction in mesangial matrix volume and mesangial volume occurred in the candesartan group , although changes in morphological parameters were similar between groups . Office blood pressure was significantly lower in the candesartan group at follow-up than in the placebo group . Deterioration in morphological parameters observed in earlier studies of our patients did not become worse during treatment with candesartan or placebo . The effects of candesartan , with reduction in morphological parameters and lowering of blood pressure , might influence future treatment of glomerulopathy in type 1 diabetes patients .
34505
Intervention_Pharmacological
candesartan
34506
Intervention_Control
placebo-controlled
34507
Intervention_Pharmacological
candesartan
34508
Intervention_Control
placebo-controlled
34509
Intervention_Control
placebo
34510
Intervention_Pharmacological
candesartan
34511
Intervention_Pharmacological
candesartan
34512
Intervention_Control
placebo
34513
Intervention_Pharmacological
candesartan
34514
Intervention_Control
placebo
34515
Intervention_Pharmacological
candesartan
34516
Outcome_Physical
diabetes glomerulopathy :
34517
Outcome_Physical
diabetic glomerulopathy
34518
Outcome_Adverse-effects
microalbuminuria and/or hypertension
34519
Outcome_Physical
mesangial matrix volume and mesangial volume
34520
Outcome_Physical
morphological parameters
34521
Outcome_Physical
Office blood pressure
34522
Outcome_Physical
morphological parameters
34523
Outcome_Physical
morphological parameters
34524
Outcome_Other
lowering of blood pressure
34525
Participant_Condition
young normoalbuminuric and normotensive patients with type 1 diabetes